New pill hopes to ease rare mitochondrial disease
NCT ID NCT06644534
First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests an oral drug called TTI-0102 in 12 people with MELAS, a rare genetic disorder that causes muscle weakness, strokes, and fatigue. Participants receive either the drug or a placebo for 6 months. Researchers will measure walking ability, fatigue, and quality of life to see if the drug helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TTI-0102 (cysteamine-pantetheine disulfide)
- What this could lead to
- If it works, this could point toward a treatment that improves daily function and reduces fatigue for people with MELAS.
- What could go wrong
- This is a very small early-phase trial with only 12 participants, so results may not apply to everyone. The drug may not show clear benefit or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELAS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Angers University Hospital Center (CHU Angers)
Angers, 49100, France
-
Radboud University Medical Center
Nijmegen, 6500 HB, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.